Vaccinex, Inc. (NASDAQ:VCNX) Short Interest Up 157.1% in April

Vaccinex, Inc. (NASDAQ:VCNX) saw a large increase in short interest in the month of April. As of April 15th, there was short interest totalling 16,200 shares, an increase of 157.1% from the March 31st total of 6,300 shares. Currently, 3.0% of the company’s shares are short sold. Based on an average daily trading volume, of 13,200 shares, the days-to-cover ratio is currently 1.2 days.

Institutional Trading of Vaccinex

An institutional investor recently bought a new position in Vaccinex stock. Armistice Capital LLC purchased a new position in shares of Vaccinex, Inc. (NASDAQ:VCNX) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 680,000 shares of the company’s stock, valued at approximately $768,000. Armistice Capital LLC owned approximately 15.45% of Vaccinex as of its most recent SEC filing. 50.11% of the stock is currently owned by hedge funds and other institutional investors.

Vaccinex Price Performance

VCNX opened at $5.83 on Friday. Vaccinex has a fifty-two week low of $4.43 and a fifty-two week high of $100.80. The company has a market cap of $7.17 million, a price-to-earnings ratio of -0.06 and a beta of 0.74. The firm has a 50 day simple moving average of $7.33 and a 200 day simple moving average of $9.50.

Vaccinex (NASDAQ:VCNX) last announced its quarterly earnings data on Tuesday, April 2nd. The company reported ($39.40) EPS for the quarter.

About Vaccinex

Vaccinex, Inc, a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D.